P2 injection of scAAV9-Abt1 did not significantly alter FL-IGHMBP2 levels, suggesting that SMARD1-nmd disease pathology was not modified by ABT1 through increasing IGHMBP2 protein (Figure 7, B and C). This evidence concerns the gene IGHMBP2 and glycogen storage disease VI.